Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2% – Should You Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was up 5.2% on Monday . The company traded as high as $40.99 and last traded at $40.99. Approximately 84,013 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 714,662 shares. The stock had previously closed at $38.97.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AGIO shares. Royal Bank of Canada lifted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Finally, Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Performance

The company has a 50-day moving average price of $50.02 and a 200-day moving average price of $46.76. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 3.73 and a beta of 0.80.

Insider Activity

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC increased its position in Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after purchasing an additional 63,900 shares during the period. State Street Corp increased its position in Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $97,199,000. Geode Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after acquiring an additional 6,101 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after acquiring an additional 855,739 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.